Table 2.
Changes in antimicrobial non-susceptibility rates by type of infection (a), age group (b) and period (c). Percentages correspond to EUCAST clinical breakpoints of non-susceptibility for penicillin (>0.06 mg/L), amoxicillin (>0.5 mg/L) and cefotaxime (>0.5 mg/L) and resistance for erythromycin (>0.5 mg/L) and levofloxacin (>2 mg/L). Statistically significant results are highlighted in bold. MIC50 and MIC90 are given in mg/L.
| (a) | BPP (n = 433) | Non-BPP (n = 462) | |||||
| Antibiotic | MIC50 | MIC90 | % | MIC50 | MIC90 | % | p-Value |
| Penicillin Amoxicillin |
<0.06 | 1 | 26% | <0.06 | 2 | 29% | 0.29 |
| <0.06 | 1 | 11% | <0.06 | 2 | 17% | 0.009 | |
| Cefotaxime Erythromycin |
<0.06 | 0.5 | 9% | <0.06 | 1 | 10% | 0.63 |
| <0.25 | >32 | 21% | <0.25 | >32 | 23% | 0.59 | |
| Levofloxacin | 1 | 1 | 1% | 0.5 | 1 | 2% | 0.44 |
| (b) | 18–64 (n = 336) | >65 (n = 559) | |||||
| Antibiotic | MIC50 | MIC90 | % | MIC50 | MIC90 | % | p-Value |
| Penicillin Amoxicillin |
<0.06 | 1 | 24% | <0.06 | 2 | 30% | 0.045 |
| <0.06 | 1 | 13% | <0.06 | 2 | 14% | 0.76 | |
| Cefotaxime Erythromycin |
<0.06 | 0.5 | 9% | <0.06 | 1 | 10% | 0.48 |
| <0.25 | >32 | 18% | <0.25 | >32 | 24% | 0.037 | |
| Levofloxacin | 1 | 1 | 1% | 1 | 1 | 2% | 0.39 |
| (c) | 2011–13 (n = 303) | 2017–19 (n = 277) | |||||
| Antibiotic | MIC50 | MIC90 | % | MIC50 | MIC90 | % | p-Value |
| Penicillin Amoxicillin |
<0.06 | 1 | 31% | <0.06 | 2 | 26% | 0.15 |
| <0.06 | 1 | 14% | <0.06 | 2 | 15% | 0.72 | |
| Cefotaxime Erythromycin |
<0.06 | 0.5 | 10% | <0.06 | 0.5 | 8% | 0.46 |
| <0.25 | >32 | 27% | <0.25 | >32 | 19% | 0.04 | |
| Levofloxacin | 1 | 1 | 2% | 1 | 1 | 1% | 0.7 |